Sterling Pharma Solutions
- Company typePrivate
- Founded1969
- HeadquartersCramlington, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
Sterling Pharma Solutions firmographics
Firmographics- Name
- Sterling Pharma Solutions
- Legal name
- Sterling Pharma Solutions
- Website
- https://sterlingpharmasolutions.com
- Company type
- Private
- Founded year
- 1969
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Sterling Pharma Solutions industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Sterling Pharma Solutions is headquartered
LocationHeadquarters
- HQ city
- Cramlington
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Sterling Pharma Solutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Sterling Pharma Solutions product offering
Product offeringCore offering
Sterling Pharma Solutions is a UK-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides small molecule API development and manufacturing services, high-potency API production, and antibody-drug conjugate (ADC) manufacturing for the global pharmaceutical industry. The company supports both early-stage and commercial-scale manufacturing and has expanded its complex process chemistry capabilities through the October 2023 acquisition of NewChem Technologies Ltd.
Product overview
Sterling Pharma Solutions operates as a pharmaceutical contract development and manufacturing organization (CDMO) providing small molecule and high-potency API manufacturing services. The company's portfolio includes complex process chemistry capabilities (enhanced through the October 2023 acquisition of NewChem Technologies Ltd.) and ADC manufacturing services for the oncology sector. The company positions itself within the broader contract research and manufacturing services (CRAMS) market.
Differentiator
Problem solved
Functional benefit
Products and services
- High-Potency API Manufacturing Contract manufacturing services for antibody-drug conjugates (ADCs) and oncology APIs, supporting both early-stage and commercial-scale manufacturing for pharmaceutical customers.
- Small Molecule API Development and Manufacturing End-to-end contract research and manufacturing services for small molecule active pharmaceutical ingredients, offered to the global pharmaceutical industry.
- Complex Process Chemistry Services Specialized process chemistry services for complex pharmaceutical molecules, provided through the acquired NewChem Technologies Ltd. business unit within Sterling Pharma Solutions.
- Continuous Manufacturing Services Continuous manufacturing technology applied to API production, capable of reducing operating costs by up to 50% and decreasing manufacturing cycle times by 80%.
Quantifiable outcome
- Continuous manufacturing can reduce operating costs by up to 50% and decrease manufacturing cycle times by 80%
Companies that use Sterling Pharma Solutions
Customer profileSegments2 records
Ideal customer profiles2 records
Sterling Pharma Solutions technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sterling Pharma Solutions partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- SoligenixflagshipSterling Pharma Solutions has a partnership with Soligenix for oncology API development. This collaboration represents Sterling's commitment to specialized capabilities in cancer therapeutic manufacturing within the pharmaceutical contract services sector.
- NewChem Technologies Ltd.coreSterling Pharma Solutions acquired NewChem Technologies Ltd. in October 2023. This acquisition exemplifies strategic consolidation trends in the CRAMS sector, strengthening Sterling's capabilities in complex process chemistry and expanding its service offerings for pharmaceutical manufacturing.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Sterling Pharma Solutions competitors and assessment
Company assessmentDirect peers
- Almac Group: UK/Northern Ireland-based CDMO offering API development, manufacturing, and pharmaceutical services. Directly comparable as a UK-headquartered, privately-held CDMO with similar scale and a comparable mix of API and finished dosage form services.
- Cambrex: US-headquartered CDMO specializing in small molecule API development and manufacturing. Directly competes with Sterling in the small-molecule CDMO space with comparable service offerings and customer base.
- Hovione: Portugal-based CDMO focused on complex API manufacturing, including highly potent and particle engineering. A direct peer given overlapping capabilities in complex chemistry, high-potency APIs, and contract manufacturing services.
- Recipharm: European CDMO offering development and manufacturing services for small molecule APIs and finished dosage forms. Comparable as a mid-to-large privately-held European CDMO with similar service breadth.
- Aenova Group: European CDMO providing solid dosage form development, manufacturing, and packaging services. Comparable as a European-based contract manufacturer serving pharma developers across multiple dosage forms.
- Curia (formerly AMRI): Global CDMO offering API development and manufacturing, drug product services, and biologics. A direct competitor in small molecule API manufacturing and contract services for pharmaceutical developers.
- Seqens: France-based integrated pharmaceutical and specialty chemicals company offering API manufacturing and custom synthesis. Comparable as a European-headquartered CDMO with similar small molecule and complex chemistry focus.
Broad incumbents
- WuXi STA (WuXi AppTec): Large global CDMO with extensive small molecule API and drug product capabilities. A broad incumbent in the same market space, though with significantly larger scale and geographic reach.
- Lonza Pharma & Biotech: Swiss-based global CDMO offering API and biologics manufacturing services. A broad incumbent that competes with Sterling across multiple service lines, particularly in API manufacturing for pharma developers.
Emerging players
- Quotient Sciences: UK-based CDMO offering drug development, formulation, and clinical manufacturing services. Comparable as a UK-headquartered CDMO focused on early-stage development and small molecule services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
Sterling Pharma Solutions social profiles
Digital presenceSterling Pharma Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sterling Pharma Solutions leadership team
Management profileNumber of profiles
Profiles1 record
Sterling Pharma Solutions subsidiaries and ownership
Company hierarchySubsidiaries1 record
Sterling Pharma Solutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sterling Pharma Solutions M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sterling Pharma Solutions
What does Sterling Pharma Solutions do?
Sterling Pharma Solutions is a UK-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides small molecule API development and manufacturing services, high-potency API production, and antibody-drug conjugate (ADC) manufacturing for the global pharmaceutical industry. The company supports both early-stage and commercial-scale manufacturing and has expanded its complex process chemistry capabilities through the October 2023 acquisition of NewChem Technologies Ltd.
Is Sterling Pharma Solutions a public or private company?
Sterling Pharma Solutions is a private company. It is classified as unknown and is currently operating.
When was Sterling Pharma Solutions founded?
Sterling Pharma Solutions was founded in 1969. It employs 1,001 to 5,000 people.
Where is Sterling Pharma Solutions based?
Sterling Pharma Solutions is headquartered in Cramlington, United Kingdom, in the Europe region.
Who are Sterling Pharma Solutions's main competitors?
Direct peers on record are Almac Group, Cambrex, Hovione, Recipharm, Aenova Group, Curia (formerly AMRI) and Seqens. Broad incumbents are WuXi STA (WuXi AppTec) and Lonza Pharma & Biotech. Quotient Sciences is listed as an emerging player.
Does Sterling Pharma Solutions have an API?
No public API is recorded for Sterling Pharma Solutions.
What industry is Sterling Pharma Solutions in?
Sterling Pharma Solutions's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 3254 and its SIC code is 2834.